Price$14.67+0.40 (+2.84%)
01:30 PM01:45 PM
News · 26 weeks46+40%
2025-12-072026-05-31
Mix1790d
- Insider9(53%)
- SEC Filings4(24%)
- Earnings3(18%)
- Other1(6%)
Latest news
25 items- INSIDERDirector Davis Timothy E Jr exercised 12,064 shares at a strike of $4.32 and sold $104,187 worth of shares (7,280 units at $14.31), increasing direct ownership by 8% to 65,722 units (SEC Form 4)4 - SI-BONE, Inc. (0001459839) (Issuer)
- INSIDERChief Executive Officer Francis Laura sold $220,000 worth of shares (14,957 units at $14.71), decreasing direct ownership by 8% to 503,444 units (SEC Form 4) to cover withholding tax4 - SI-BONE, Inc. (0001459839) (Issuer)
- INSIDERSVP, Ops & Adm/Chief Legal Ofr Pisetsky Michael A. sold $54,527 worth of shares (3,726 units at $14.63), decreasing direct ownership by 0.82% to 280,509 units (SEC Form 4) (tax liability)4 - SI-BONE, Inc. (0001459839) (Issuer)
- INSIDERChief Financial Officer Maheshwari Anshul sold $68,523 worth of shares (4,666 units at $14.69), decreasing direct ownership by 1% to 259,877 units (SEC Form 4) to cover withholding tax4 - SI-BONE, Inc. (0001459839) (Issuer)
- SECSEC Form 10-Q filed by SI-BONE Inc.10-Q - SI-BONE, Inc. (0001459839) (Filer)
- SECSI-BONE Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - SI-BONE, Inc. (0001459839) (Filer)
- PRSI-BONE, Inc. Reports Financial Results for the First Quarter 2026 and Raises 2026 GuidanceFirst Quarter 2026 Financial Highlights (all comparisons are to the prior year period) Worldwide revenue of $52.6 million, representing growth of 11.2%U.S. revenue of $49.3 million, representing growth of 10.0%Gross margin of 79.8% Net loss of $4.3 million, representing an improvement of 33.8% Adjusted EBITDA of $2.5 million, representing an improvement of over 440%$144.7 million in cash and equivalents Recent Operational Highlights (any comparisons are to the prior year period) Over 1,650 active U.S. physicians, representing growth of 17% $2.2 million in trailing 12-month average revenue per territory, representing an increase of 11%Expanded international presence with the launch
- INSIDERDirector Dunn Jeffrey W sold $4,432 worth of shares (337 units at $13.15), decreasing direct ownership by 4% to 9,157 units (SEC Form 4) to satisfy withholding tax4 - SI-BONE, Inc. (0001459839) (Issuer)
- PRSI-BONE To Present at BofA Securities 2026 Healthcare Conference on May 12, 2026SANTA CLARA, Calif., April 30, 2026 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (NASDAQ:SIBN), the global leader in developing procedural solutions to address clinical challenges associated with compromised bone, today announced that the company will be participating in the upcoming 2026 BofA Securities Healthcare Conference in Las Vegas, NV. Management will be hosting a fireside chat on Tuesday, May 12, 2026, at 8:00 a.m. Pacific Time/11:00 a.m. Eastern Time. Investors interested in listening to the conference call may do so by registering at this link: https://bofa.veracast.com/webcasts/bofa/healthcare2026/f3F578.cfm. Live audio of the webcast will be available on the "Investors" section of the c
- SECSEC Form DEFA14A filed by SI-BONE Inc.DEFA14A - SI-BONE, Inc. (0001459839) (Filer)
- SECSEC Form DEF 14A filed by SI-BONE Inc.DEF 14A - SI-BONE, Inc. (0001459839) (Filer)
- PRSI-BONE To Report First-Quarter 2026 Financial Results on May 11, 2026SANTA CLARA, Calif., April 20, 2026 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (NASDAQ:SIBN), the global leader in developing procedural solutions to address clinical challenges associated with compromised bone, today announced it will report financial results for the first quarter of 2026 after market close on Monday, May 11, 2026. Management will host a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time Investors interested in listening to the conference call may do so by registering at this link: https://edge.media-server.com/mmc/p/vde24u4q. Live audio of the webcast will be available on the "Investors" section of the company's website at: www.si-bone.com. The webcast
- INSIDERSEC Form 4 filed by Hinckley Greg K4 - SI-BONE, Inc. (0001459839) (Issuer)
- INSIDERSEC Form 4 filed by Maheshwari Anshul4 - SI-BONE, Inc. (0001459839) (Issuer)
- INSIDERSEC Form 4 filed by Pisetsky Michael A.4 - SI-BONE, Inc. (0001459839) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by SI-BONE Inc.SCHEDULE 13G/A - SI-BONE, Inc. (0001459839) (Subject)
- INSIDERDirector Nishimura Mika sold $56,700 worth of shares (4,100 units at $13.83), decreasing direct ownership by 11% to 32,716 units (SEC Form 4)4 - SI-BONE, Inc. (0001459839) (Issuer)
- SECSEC Form S-8 filed by SI-BONE Inc.S-8 - SI-BONE, Inc. (0001459839) (Filer)
- SECSEC Form S-3ASR filed by SI-BONE Inc.S-3ASR - SI-BONE, Inc. (0001459839) (Filer)
- SECSEC Form 10-K filed by SI-BONE Inc.10-K - SI-BONE, Inc. (0001459839) (Filer)
- PRSmith+Nephew signs distribution agreement with SI-BONETrauma and Extremities partnership aligns disciplined approach to portfolio optimization and focuses on delivering long-term value for surgeons and patients Smith+Nephew ((LSE:SN, NYSE:SNN), the global medical technology company, today announced it has signed a distribution agreement with SI-BONE, focused on their innovative iFuse TORQ portfolio. This collaboration expands the Smith+Nephew portfolio offerings for percutaneous pelvic fracture fixation procedures and strengthens our position in high-frequency, high-impact trauma procedures."We're incredibly excited to partner with SI-BONE," said Scott Gunn, Vice President Trauma, Extremities and Shoulder. "This collaboration reflects a share
- SECSI-BONE Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Results of Operations and Financial Condition, Leadership Update, Financial Statements and Exhibits8-K - SI-BONE, Inc. (0001459839) (Filer)
- PRSI-BONE, Inc. Reports Record Financial Results for the Fourth Quarter 2025 and Issues 2026 GuidanceAchieves 20% worldwide revenue growth and positive adjusted EBITDA for Fiscal Year 2025Generates free cash flow in the Fourth Quarter 2025 SANTA CLARA, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (NASDAQ:SIBN), the global leader in developing procedural solutions to address clinical challenges associated with compromised bone, today reported financial results for the fourth quarter and full year ended December 31, 2025. Fourth Quarter 2025 Financial Highlights (all comparisons are to the prior year period) Worldwide revenue of $56.3 million, representing growth of 15.0%U.S. revenue of $53.5 million, representing growth of 13.9%Gross margin of 79.0%Net loss of $1.6 million, r
- INSIDERRecupero Anthony J sold $324,204 worth of shares (21,049 units at $15.40), decreasing direct ownership by 8% to 243,418 units (SEC Form 4)4 - SI-BONE, Inc. (0001459839) (Issuer)
- INSIDERSVP, Ops & Adm/Chief Legal Ofr Pisetsky Michael A. was granted 78,294 shares and sold $318,642 worth of shares (20,756 units at $15.35), increasing direct ownership by 25% to 285,974 units (SEC Form 4)4 - SI-BONE, Inc. (0001459839) (Issuer)
SIBN FAQ
7 questionsWhat does SI-BONE Inc. do?
SI-BONE, Inc., a medical device company, develops implantable devices used in the surgical treatment of the sacropelvic anatomy in the United States and Internationally. The company offers iFuse, a minimally invasive surgical implant system, which is intended to fuse the sacroiliac joint to treat sacroiliac joint dysfunction that causes lower back pain. SI-BONE, Inc. was incorporated in 2008 and is headquartered in Santa Clara, California.Where does SIBN stock trade?
SI-BONE Inc. (SIBN) is listed on NASDAQ.What sector and industry is SIBN in?
SI-BONE Inc. operates in the Health Care sector, Medical/Dental Instruments industry.When did SI-BONE Inc. go public?
SI-BONE Inc. (SIBN) completed its IPO in 2018.What are analysts saying about SIBN?
SI-BONE Inc. has had 8 recent analyst actions on file. The most recent action was from TD Cowen: Buy with a $2100.00 price target on 2026-01-27. Recent price targets range from $1900.00 to $3600.00.What companies are similar to SIBN?
Notable peers in the same industry include SYK (Stryker Corporation), MMM (3M Company), BSX (Boston Scientific Corporation), MDLN (Medline Inc.), BDX (Becton Dickinson and Company). Compare SIBN side-by-side with any of them on Quantisnow.How can I track SIBN on Quantisnow?
Quantisnow aggregates SI-BONE Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow SIBN to receive live email and push alerts on every new disclosure.